Please login to the form below

Not currently logged in
Email:
Password:

EMA set to review Teva’s migraine injection

Fremanezumab could be approved for prophylactic use of migraines

Teva

The European Medicines Agency (EMA) has accepted Teva’s marketing authorisation application (MAA) for its migraine prevention medicine fremanezumab.

Teva’s injection, an anti-calcitonin gene-related peptide (CGRP) monoclonal antibody administered quarterly or monthly, is up for review to prevent episodic and chronic migraine in adults.

Ernesto Aycardi, vice president head of clinical trial execution at Teva, said: “With limited availability of preventive therapy options that target the underlying biological mechanisms of migraine, the MAA acceptance represents a major step toward advancing the treatment paradigm for the migraine community.”

The application seeking approval includes positive results from two-phase III trials in chronic migraine and episodic migraine, which - after evaluating both quarterly and monthly dosing regimens - found fremanezumab achieving statistically significant results across all trial endpoints.

More specifically the HALO trials - which were randomised, double-blind placebo-controlled studies - compared safety, tolerability and efficacy of the Teva’s medicine compared to placebo.

Aycardi continued: “These two significant regulatory milestones in the migraine indication, combined with our clinical development programmes for fremanezumab in cluster headache and post-traumatic headache, highlight Teva’s commitment to patients worldwide with these debilitating conditions.”

Fremanezumab is also being investigated for the prevention of chronic and episodic cluster headache as part of the phase III ENFORCE clinical research programme, which has been granted fast track designation by the US Food and Drug Administration (FDA).

Trials are expected to conclude in early 2019, and if all goes well with the studies then the Israeli pharma group could be gunning up for a big win, as it could potentially be the first to get approval of a cluster headache medication.

Cluster headaches - which are more commonly seen in men - normally come in sporadic episodes and suffers tend to feel severe pain along with a bunch of side effects including one red eye, smaller pupil in one eye and the drooping and swelling of one eyelid.

Article by
Gemma Jones

5th February 2018

From: Regulatory

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
PharmiWeb Solutions

PharmiWeb Solutions creates, delivers and manages digital solutions for the pharmaceutical and healthcare segment. From digital marketing, to patient education...

Latest intelligence

Is the pharma business model ready for precision medicine?
Precision medicine promises to revolutionise patient outcomes and reduce costs for industry but is pharma ready for it? Blue Latitude Health co-founder Head of Strategy Fred Bassett explores the challenges...
ABPI2018
The NHS and ABPI at 70: inching closer to the triple win
The NHS and UK pharma’s ABPI both turn 70 this year. After years of transactional relationships, there’s a will to work more closely - but friction on prices and value...
What pharma marketers can learn from behavioural science
Pharma behavioural science and traditional emotional marketing create a powerful mix of techniques that have impact on real lives....

Infographics